Ordaos specializes in creating miniature proteins used in drug developments. The funding round was led by Middleland Capital’s VTC Ventures, according to an Aug. 25 Ordaos news release.
“Ordaos’ class of mini-proteins — Ordaos miniPRO — transforms the role of proteins in drug discovery by providing the power and performance of antibodies while being more stable, configurable and easier to manufacture,” Ordaos CEO David Longo said in the release. “This investment will enable us to maximize drug candidate delivery speed, novelty, and probability of clinical success that provides drug hunters what they have been dreaming of.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
